RNA Phage VLP-Based Vaccine Platforms

David S. Peabody; Julianne Peabody; Steven B. Bradfute; Bryce Chackerian

doi:10.3390/ph14080764

Pharmaceuticals (Aug 2021)

RNA Phage VLP-Based Vaccine Platforms

David S. Peabody,
Julianne Peabody,
Steven B. Bradfute,
Bryce Chackerian

Affiliations

David S. Peabody: Department of Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, NM 87131, USA
Julianne Peabody: Department of Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, NM 87131, USA
Steven B. Bradfute: Center for Global Health, Division of Infectious Diseases, Department of Internal Medicine, University of New Mexico, Albuquerque, NM 505, USA
Bryce Chackerian: Department of Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, NM 87131, USA

DOI: https://doi.org/10.3390/ph14080764
Journal volume & issue: Vol. 14, no. 8
p. 764

Abstract

Read online

Virus-like particles from a variety of RNA bacteriophages have turned out to be useful platforms for delivery of vaccine antigens in a highly immunogenic format. Here we update the current state of development of RNA phage VLPs as platforms for presentation of diverse antigens by genetic, enzymatic, and chemical display methods.

Published in Pharmaceuticals

ISSN: 1424-8247 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Medicine: Pharmacy and materia medica
Website: http://www.mdpi.com/journal/pharmaceuticals/

About the journal

Abstract

Keywords